🇪🇺 DANICOPAN in European Union

EMA authorised DANICOPAN on 19 April 2024

Marketing authorisation

EMA — authorised 19 April 2024

  • Application: EMEA/H/C/005517
  • Marketing authorisation holder: Alexion Europe SAS
  • Local brand name: Voydeya
  • Indication: Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia 
  • Pathway: orphan, PRIME
  • Status: approved

Read official source →

DANICOPAN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is DANICOPAN approved in European Union?

Yes. EMA authorised it on 19 April 2024.

Who is the marketing authorisation holder for DANICOPAN in European Union?

Alexion Europe SAS holds the EU marketing authorisation.